SYDNEY, AUSTRALIA--(Marketwired - Jun 21, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce initial safety data from the first cohort of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback